pre-IPO PHARMA

COMPANY OVERVIEW

MEBIAS, an emerging leader in the field of pathway-selective G-protein coupled receptor (GPCR) drug discovery. MEBIAS was founded to establish an alternative discovery model, offering a validated, rapid, and highly efficient drug discovery platform.


LOCATION

  • Philadelphia, PA, USA

  • THERAPEUTIC AREAS

  • Pain

  • WEBSITE

    http://mebiasdiscovery.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Oct 29, 2020

    Mebias Discovery Receives Grant from NIDA to Advance MEB-1170 as an Analgesic Drug Candidate for the Prevention and Treatment of Opioid Use Disorder


    Sep 24, 2018

    MEBIAS Discovery Receives Grant from NIDA to Advance Its Signaling-Pathway Selective Mu-Opioid Receptor Drug Candidate


    Oct 16, 2017

    MEBIAS Discovery LLC Presents Pre-Clinical Data on Mu Opioid Receptor Pain Compounds at ADDC


    For More Press Releases


    Google Analytics Alternative